<DOC>
	<DOCNO>NCT00253565</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving imatinib mesylate together capecitabine may kill tumor cell . PURPOSE : This phase I trial study side effect best dose imatinib mesylate give together capecitabine treat patient advance solid tumor .</brief_summary>
	<brief_title>Imatinib Mesylate Capecitabine Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose imatinib mesylate administer capecitabine patient advance malignant solid tumor . Secondary - Determine non-dose-limiting toxic effect regimen patient . - Determine , preliminarily , clinical activity regimen patient . - Determine pharmacokinetics pharmacogenetics regimen patient . - Determine , preliminarily , effect regimen wound angiogenesis patient . - Correlate pharmacokinetic parameter clinical toxicity , clinical activity , surrogate biomarker activity regimen patient . OUTLINE : This dose escalation study imatinib mesylate . Patients receive oral capecitabine twice daily day 1-14 oral imatinib mesylate twice daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts patient receive escalate dos imatinib mesylate maximum tolerate dose determine . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor standard effective therapy exist OR therapy refuse Previously treat brain metastasis currently asymptomatic allow PATIENT CHARACTERISTICS : Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 2,000/mm^3 Platelet count &gt; 100,000 mm^3 Hemoglobin &gt; 9.0 g/dL Hepatic Alkaline phosphatase &lt; 2.5 time upper limit normal ( ULN ) SGOT SGPT &lt; 2.5 time ULN Bilirubin &lt; 1.5 time ULN Renal Creatinine clearance &gt; 50 mL/min Cardiovascular No congestive heart failure No symptomatic coronary artery disease No uncontrolled cardiac arrhythmia No myocardial infarction within past 12 month No clinically significant cardiac disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No prior unanticipated severe reaction fluoropyrimidine therapy No known sensitivity fluorouracil PRIOR CONCURRENT THERAPY : Biologic therapy More 28 day since prior biologic therapy Chemotherapy More 28 day since prior chemotherapy ( 42 day nitrosoureas mitomycin C ) Endocrine therapy At least 90 day since prior steroid treatment brain metastases More 28 day since prior hormonal therapy Radiotherapy At least 90 day since prior radiotherapy treatment brain metastases More 28 day since prior radiotherapy No prior pelvic radiotherapy &gt; 30 % bone marrow Surgery More 28 day since prior surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>